Ardelyx (ARDX) - Stock Price & Dividends

Ardelyx, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines to treat gastrointestinal and cardiorenal diseases. Their primary goal is to improve the lives of patients suffering from these conditions.

The company's lead product candidate, tenapanor, is designed to treat patients with irritable bowel syndrome with constipation (IBS-C). This condition affects millions of people worldwide, causing uncomfortable symptoms like abdominal pain, bloating, and changes in bowel movements. Tenapanor has the potential to provide relief to these patients.

In addition to tenapanor, Ardelyx is developing XPHOZAH, a medication in Phase III clinical trials aimed at reducing high levels of phosphorus in the blood of adults with chronic kidney disease (CKD) who are on dialysis. Elevated phosphorus levels can lead to serious health complications, including heart disease and bone damage.

Ardelyx is also working on RDX013, a potassium secretagogue that targets hyperkalemia, a condition characterized by elevated potassium levels in the blood. This condition is common in patients with kidney and/or heart failure, and can lead to life-threatening complications if left untreated.

The company is also developing RDX020, a treatment for metabolic acidosis, a serious electrolyte disorder that can cause a range of symptoms, including fatigue, muscle weakness, and rapid breathing.

Ardelyx has established partnerships with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. to develop and commercialize tenapanor in their respective territories. These collaborations will help expand the reach of Ardelyx's innovative medicines to more patients worldwide.

Headquartered in Waltham, Massachusetts, Ardelyx, Inc. was founded in 2007 and was formerly known as Nteryx, Inc. before changing its name in 2008. For more information about the company and its mission, visit their website at https://www.ardelyx.com.